Julia Hengst

Sep 1, 2024 | bioprocessintl.com | Julia Hengst

Manufacturing chimeric antigen receptor (CAR) T cells involves several key challenges, including high manufacturing costs, unsustainable failure rates, long vein-to-vein processes, and lengthy quality-control (QC) and product-release activities. With support from Sartorius, scientists in the laboratory of Professor Qasim Rafiq (University College London) sought to mitigate these challenges and improve potency and cell yield with intensified production.

Nov 2, 2023 | bioprocessintl.com | Julia Hengst |Diane McCarthy |Brian Gazaille

Sep 23 - Sep 26, 2024Learn from the brightest minds in bioprocessing!The BPI US 2024 scientific agenda includes 200+ of the industry's top scientists to present the latest updates on how to improve efficiencies across all phases of biopharmaceutical development and production. Learn More